Top Companies in the Minimally Invasive Surgery

The minimally invasive surgery market is projected to reach USD 199.30 billion by 2030, up from USD 94.45 billion in 2025, at a CAGR of 16.1% from 2025 to 2030. The minimally invasive surgery market is experiencing significant growth due to rising patient demand for procedures with shorter recovery times, fewer hospital stays, and lower post-operative complications. Technological advances such as robotic-assisted surgery, improved imaging, and precision instruments are improving surgical efficiency and outcomes. The increasing prevalence of chronic diseases and aging populations are driving higher procedural volumes worldwide. Moreover, favorable reimbursement policies and the growing adoption of MIS in emerging economies are further speeding up market growth. Healthcare providers are also increasingly using MIS to improve operational efficiency and cut overall treatment costs.

Some of the major players in the minimally invasive surgery market with a significant global presence include Medtronic (Ireland), Johnson & Johnson (US), Stryker (US), Boston Scientific Corporation (US), Abbott (US), Zimmer Biomet (US), Boston Scientific Corporation (US), GE Healthcare (US), and others. These companies have implemented various organic and inorganic growth strategies, such as acquisitions, product launches, product approvals, and partnerships, to strengthen their international presence and gain a larger share of the minimally invasive surgery market. These strategies have enabled market players to expand across different regions by offering minimally invasive surgery products.

To know about the assumptions considered for the study download the pdf brochure

• In March 2025, Boston Scientific Corporation has entered into a definitive agreement to acquire SoniVie Ltd., enhancing its portfolio with the TIVUS Intravascular Ultrasound System and strengthening its position in the high-growth minimally invasive surgery market.
• In January 2025, Boston Scientific Corporation announced a definitive agreement to acquire Bolt Medical, Inc., adding its advanced laser-based intravascular lithotripsy (IVL) platform to enhance treatment options for coronary and peripheral artery disease and expand its cardiovascular portfolio.
• In February 2024, Zimmer Biomet Holdings, Inc. received 510(k) clearance from the US FDA for its ROSA Shoulder System, expanding its robotic-assisted surgery portfolio to include shoulder replacement procedures and strengthening its position in orthopedics innovation.
• In November 2023, Medtronic received FDA approval for its minimally invasive Symplicity Spyral renal denervation system for hypertension management and is set to begin immediate commercialization across target areas markets.

Some of the prominent players operating in the market include, are Medtronic (Ireland), Johnson & Johnson (US), Stryker (US), Boston Scientific Corporation (US), Siemens Healthineers AG (Germany), Abbott (US), GE HealthCare (US), Koninklijke Philips N.V. (Netherland), Intuitive Surgical Operations, Inc. (US), Zimmer Biomet (US), FUJIFILM Corporation (Japan).

Medtronic (US):

Medtronic stands as a pivotal player in the minimally invasive surgery sector, bolstered by a comprehensive product portfolio, robust innovative capacity, and a well-established global footprint. The company advances MIS solutions through its distinct Neuroscience, Medical Surgical, and Cardiovascular divisions, deploying sophisticated technologies across various therapeutic domains. Medtronic's strategic initiatives, focusing on both organic development and strategic acquisitions, have facilitated sustained growth and a continuous pipeline of product innovation. In FY2024, the company allocated 8.1% of its revenue—amounting to USD 2,732 million—toward research and development, highlighting a strong commitment to technological progress. Notable regulatory achievements, including FDA approval for its minimally invasive renal denervation system, alongside the worldwide deployment of its robotic-assisted surgical platform, underscore Medtronic’s proficiency in accelerating the market introduction of advanced solutions. The company's extensive operations in over 150 countries foster broad adoption and commercial scalability of its offerings. Collectively, these attributes—global reach, relentless innovation, and strategic commercial execution—consolidate Medtronic's leadership position in the MIS arena, as it consistently delivers next-generation surgical technologies aimed at enhancing patient outcomes.

Johnson & Johnson (US):

Johnson & Johnson is a prominent player in the minimally invasive surgery market, characterized by its innovation-driven approach, a diversified MedTech portfolio, and a robust global presence. Through its subsidiaries, Ethicon and DePuy Synthes, the company provides a wide array of MIS solutions spanning both surgical and orthopedic applications. In FY2024, Johnson & Johnson committed USD 3,703 million—representing 11.6% of its MedTech segment sales—to research and development, underscoring its strong focus on advancing surgical technologies. The company embraces a balanced strategy for growth that integrates both organic development and strategic acquisitions, emphasizing product innovation and digital transformation. The receipt of regulatory approval for the Monarch robotic-assisted system in November 2025, alongside its strategic alliance with Microsoft, established in January 2022 to advance digital surgical capabilities, exemplifies its proactive stance in investing in digital health and intelligent surgical systems. Johnson & Johnson’s extensive global footprint and strong operational execution further facilitate the widespread integration of its MIS technologies into healthcare systems. Collectively, these initiatives enhance its competitive advantage and reinforce its leadership in delivering cutting-edge, minimally invasive surgical solutions tailored to meet the dynamic needs of both clinical practitioners and patients.

Market Ranking:

The competitive landscape of the minimally invasive surgery market is primarily determined by market share analytics, secondary research, and corroboration from primary sources. The assessment accounts for revenue from a comprehensive product portfolio, innovation, and recent approvals or product launches. Notably, the market is characterized by five key players commanding a combined market share of 25%-50%. The principal entities leading this sector include Medtronic (Ireland), Johnson & Johnson (US), Siemens Healthineers AG (Germany), Zimmer Biomet (US), and Intuitive Surgical Operations, Inc. (US). Medtronic is recognized for its extensive array of sophisticated MIS products, positioning itself as a leader in technological advancement within this space. Meanwhile, Johnson & Johnson maintains a robust global footprint with a diverse portfolio designed to enhance patient outcomes in minimally invasive procedures. Siemens Healthineers AG distinguishes itself through its significant breadth of offerings and strategic focus on organic growth initiatives, further reinforcing its market presence. Zimmer Biomet and Intuitive Surgical Operations, Inc. also contribute significantly to the MIS domain by providing specialized products tailored for minimally invasive applications. The remaining 50%-75% of the market is occupied by a variety of regional and emerging players. This segmentation leads to considerable market fragmentation and simultaneously presents avenues for smaller companies to establish their presence in this evolving field.

Related Reports:

Minimally Invasive Surgery Market by Type (Surgical Device, Imaging System, Electrosurgical Device, Endoscopy Device, Medical Robotics), Application (Urological, Vascular, Oncological), End User (Hospital, Clinic, ASC) Region-Global Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets Inc.
1615 South Congress Ave.
Suite 103,
Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com